Benzinga provided stock analysis on Zymeworks on September 3, 2025.
1 report, 1 independent
Updated Sep 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Benzinga provided stock analysis on Zymeworks on September 3, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Benzinga reported stock analyst updates concerning the company Freshworks.
- Gartner transcripts were carried by Benzinga and Investing.com on November 1, 2026.
- BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.
- Benzinga reported on price target changes involving Annaly Capital Management.
Coverage
Newest first; wire copies grouped- BenzingaZymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit Zymeworks Inc. (NASDAQ:ZYME) on Tuesday decided to voluntarily discontinue clinical development of ZW171, a